CD155与PD-L1在卵巢癌及其他癌症中表达模式及免疫相关性对比
该研究探讨高级别浆液性卵巢癌(HGSC)及其他癌症中CD155与PD-L1的表达模式、肿瘤浸润淋巴细胞(TIL)关联及预后意义。结果显示CD155多表达于恶性上皮且与TIL负相关或不显著,PD-L1主要表达于肿瘤相关巨噬细胞且与TIL正相关,二者在TCGA多种癌症中预后关联亦不同,提示为非冗余免疫抑制机制。
要点
- HGSC中T细胞常共表达TIGIT与PD-1,体外扩增后TIGIT/PD-1比值显著升高。
- CD155在HGSC恶性上皮常见表达且与TIL负相关或不显著,PD-L1主要表达于巨噬细胞且与TIL正相关。
- CD155与PD-L1表达模式及预后意义在不同癌症(含HGSC)中呈现分歧,提示非冗余免疫抑制机制。
核心结论
- CD155与PD-L1呈现对比性表达模式、TIL关联及预后意义,提示二者代表非冗余的免疫抑制机制。
- CD155/TIGIT通路是HGSC及免疫冷肿瘤的有力免疫治疗靶点。
研究设计与样本
- 研究采用高维流式细胞术、多色组织成像和/或基因表达谱分析HGSC中CD155、TIGIT、PD-1、PD-L1等免疫标志物表达。
- 利用癌症基因组图谱(TCGA)对HGSC及32种其他癌症中PVR/CD155与CD274/PD-L1表达的预后意义进行生物信息学分析。
主要发现
- HGSC来源T细胞常共表达TIGIT与PD-1,经临床相关方案体外扩增后TIGIT与PD-1表达比值显著升高。
- CD155在HGSC恶性上皮常见表达,与TIL呈负相关或不显著关联。
- PD-L1主要由肿瘤相关巨噬细胞表达,与TIL呈正相关。
- CD155与PD-L1的对比模式见于HGSC患者间、同一患者不同转移灶间乃至单个肿瘤沉积内。
- PVR/CD155与CD274/PD-L1在TCGA多种癌症(含HGSC)中呈现分歧的预后关联。
临床怎么用
- CD155/TIGIT通路可作为HGSC及免疫冷肿瘤的免疫治疗靶点进行探索。
- 评估免疫抑制机制时需同时考虑CD155与PD-L1的非冗余作用,不宜互相替代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We recently showed that tumors with an immunologically 'cold' phenotype are enriched for expression of stemness-associated genes and PVR/CD155, the ligand of the immunosuppressive molecule TIGIT. To explore the therapeutic implications of this finding, we investigated the relationship between PVR/CD155 expression, tumor-infiltrating lymphocytes (TIL), and prognosis in high-grade serous ovarian cancer (HGSC) and other cancers. METHODS: Expression of CD155, TIGIT, PD-1, PD-L1, and other immune markers in HGSC was assessed by high-dimensional flow cytometry, multi-color histological imaging, and/or gene expression profiling. The prognostic significance of PVR/CD155 and CD274/PD-L1 expression was assessed bioinformatically in HGSC and 32 other cancers in The Cancer Genome Atlas. RESULTS: T cells from HGSC frequently co-expressed TIGIT and PD-1, and the ratio of TIGIT to PD-1 expression increased markedly after in vitro expansion with a clinically relevant protocol. CD155 was commonly expressed on malignant epithelium in HGSC and showed a negative or non-significant association with TIL. In contrast, PD-L1 was predominantly expressed by tumor-associated macrophages and positively associated with TIL. These contrasts between CD155 and PD-L1 were seen across HGSC patients, across metastatic sites within individual patients, and even within individual tumor deposits. PVR/CD155 and CD274/PD-L1 exhibited divergent prognostic associations across diverse cancer types in TCGA, including HGSC. CONCLUSIONS: CD155 and PD-L1 exhibit contrasting expression patterns, TIL associations and prognostic significance, suggesting they represent non-redundant immunosuppressive mechanisms. The CD155/TIGIT pathway represents a compelling immunotherapeutic target for HGSC and for immunologically cold tumors in general.
引用
- Smazynski J, Hamilton PT, Thornton S, et al. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecol Oncol. 2020. PMID: 32446718. doi:10.1016/j.ygyno.2020.04.689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。